UltraFlow St. John's Wort Enters U.S. Market

UltraFlow St. John's Wort Enters U.S. Market

PITTSBURGH--Euromed reported that a large Europeanclinical trial demonstrated its UltraFlow St. John's wort extract is safe andeffective. Based on these results, the company announced it would be makingUltraFlow available in the United States. The trial involved 11,000 patients whowere given 600 mg/d of St. John's wort (using an UltraFlow formulation), withpatients reporting significant improvements in depressive symptoms with minimalside effects, according to the company. In addition, subjects reported improvedcompliance in using a once-a-day dose.

"UltraFlow St. John's wort extract will help our customersproduce products with a much higher rate of patient compliance and unparalleledconsumer convenience," said Joe Veilleux, general manager of Euromed USA."In addition, the UltraFlow extract powder is more free flowing thanregular St. John's wort extract powders, which tend to be hygroscopic. Thismeans that tablet and capsule production can occur more smoothly on high-speedmachinery."

For more information, visit www.euromedusa.comor Booth #1212 at SupplySide East.